Gencor and its exclusive delivery systems technology partner, Pharmako Biotechnologies, will announce BioBerb, a cold-water dispersible berberine, at the upcoming SupplySide Global (SSG) trade show happening on October 27-30 in Las Vegas.
The company will also unveil new science on its branded Oleoylethanolamide (OEA) ingredient, Trpti, as well as its recently published Levagen+ study demonstrating physiological resilience to stress among female university students.
Berberine is recognised for its antioxidant and anti-inflammatory effects and it interacts with key enzymes, including AMPK, PKC and SIRT1, which are vital regulators of energy production, glucose metabolism and immune function.
Berberine also supports insulin activity, gut microbiome diversity and may stimulate GLP-1, a hormone involved in blood sugar regulation.
However, the traditional Indian Barberry, Berberis aristata, root requires high doses of berberine (up to 2 g daily) to be effective, often causing tolerability issues and adverse events, including digestive discomfort, poor tolerability and inconsistent outcomes.
BioBerb, powered by the award-winning LipiSperse dispersion technology from Pharmako, provides significantly improved absorption and bioavailability.
In a peer-reviewed clinical study, a single 188 mg dose of BioBerb delivered 801 ng/mL of total berberine into blood plasma, demonstrating unmatched bioefficacy at a low dose.
“BioBerb is not just another supplement; it’s a smarter, more advanced way to support your health,' said George Kokkinis, CEO of Pharmako Biotechnologies.
"If you're serious about optimising your energy, blood sugar and overall metabolic function, BioBerb is a clear choice."
The company will also reveal new data on its proprietary OEA ingredient, Trpti and its influence on weight management through the gut microbiome and through its effect on GLP-1 secretion and inhibition of DPP-4.
Trpti is OEA combined with LipiSperse delivery technology, making it a bioavailable form of OEA to support GLP-1 production and downregulate DPP-4, the enzyme that degrades GLP-1.
Gencor will also highlight the recently published data on Levagen+ and its ability to enhance physiological resilience in female students.
“At Gencor, innovation begins with science that genuinely impacts how people feel and perform," said John Quilter, CEO of Gencor.
"With BioBerb, Trpti and Levagen, we’re pushing the limits of what’s possible in natural metabolic and joint health support."
"These ingredients demonstrate our ongoing commitment to turning advanced clinical research into effective, accessible wellness solutions for today’s active consumers."
Gencor is also inviting SSG attendees to its educational session, featuring renowned researchers Dr Amanda Rao from RDC Global and Dr Daniele Piomelli, Director of the University of California Center for the Study of Cannabis & Cannabinoid Research and Rhizotomos Consulting.
In this 50-minute session, Dr Rao will present new research on a bioavailable form of berberine (BioBerb) and Dr Piomelli will share data on a bioavailable
form of OEA (Trpti) and its role in supporting metabolic health and weight management.
The presentation will be held on Wednesday, October 29th, at 4-4:50 PM, at the Product Development Theatre, booth #8076, Bayside B, Level 1.
Finally, Gencor will be making a global company-wide announcement, debuting exclusively on the first day of SupplySide Global, October 29th.
